Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 7/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789907 | 0.95 | CCR3 (0.61) | CCR3HRH3ACHEABL1RIN1 | |
| SCHEMBL12040802 | 0.94 | KCNH2 (0.61) | CCR3HRH3ACHEABL1RIN1 | |
| SCHEMBL12044684 | 0.94 | KCNH2 (0.61) | CCR3HRH3ACHEABL1RIN1 | |
| SCHEMBL13596997 | 0.91 | KCNH2 (0.56) | CCR3HRH3ACHEABL1RIN1 | |
| SCHEMBL13596970 | 0.91 | HRH3 (0.56) | CCR3HRH3ACHEABL1RIN1 | |
| SCHEMBL69200 | 0.90 | CCR3 (0.67) | CCR3HRH3ACHEBCHE | |
| SCHEMBL3107807 | 0.90 | CCR3 (0.71) | CCR3ACHEBCHE | |
| SCHEMBL4499239 | 0.88 | CCR3 (0.69) | CCR3ACHEBCHE | |
| SCHEMBL4499901 | 0.88 | CCR3 (0.69) | CCR3ACHEBCHE | |
| SCHEMBL17262668 | 0.85 | DRD2 (0.68) | CCR3ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-8188096-B2 | Protein kinase targeted therapeutics | NORTHWESTERN UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110166153-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2011-07-07 | — | — | US | disclosed |
| US-7919485-B2 | Protein kinase targeted therapeutics | NORTHWESTERN UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| US-20100016587-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2008025857-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-20080051410-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2008-02-28 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | CCR3 79/4885HRH3 58/4885ACHE 3889/4885 |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | CCR3 2392/4885HRH3 333/4885ACHE 768/4885 |
| US-20110166153-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885HRH3 4117/4885ACHE 4001/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | CCR3 173/4885HRH3 62/4885ACHE 3998/4885 |
| US-20100016587-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885HRH3 4117/4885ACHE 4001/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | CCR3 2392/4885HRH3 333/4885ACHE 768/4885 |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | CCR3 4495/4885HRH3 4282/4885ACHE 4761/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | CCR3 3298/4885HRH3 1194/4885ACHE 1584/4885 |
| US-20080051410-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885HRH3 4117/4885ACHE 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.